RayKnowChina Research Map
Shortlist0

Not yet recruitingNeuromyelitis optica spectrum disorderEarly phase 1

Registered title, quoted from ClinicalTrials.gov

The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.

An open trial on neuromyelitis optica spectrum disorder, registered on ClinicalTrials.gov. Led by Chinese PLA General Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorChinese PLA General Hospital中国人民解放军总医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07592754, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 65 years; sex: all

    Registered eligibility fields

  2. The Expanded Disability Status Scale (EDSS) score ≤ 8.

    Inclusion criterion 3

  3. Viral infections: Known HIV, active HBV, or active HCV.

    Exclusion criterion 1

  4. Female participants of childbearing potential must present a negative pregnancy test at screening and agree to use effective contraception throughout the study period.

    Inclusion criterion 4

    Pregnant or breastfeeding women.

    Exclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07592754, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Key Inclusion Criteria:

  • Patients must meet the 2015 International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorder (NMOSD) and test positive for AQP4 antibodies.
  • Documented evidence of at least 1 relapse within 12 months before signing the informed consent form.
  • The Expanded Disability Status Scale (EDSS) score ≤ 8.
  • Female participants of childbearing potential must present a negative pregnancy test at screening and agree to use effective contraception throughout the study period.
  • Informed consent must be obtained from the patient or their legal representative, with a signed consent form must be provided.

Key Exclusion Criteria:

  • Viral infections: Known HIV, active HBV, or active HCV.
  • Pregnant or breastfeeding women.
  • History of other autoimmune diseases requiring immunosuppressive therapy.
  • Use of any live vaccines against infectious disease within 6 weeks before enrollment.
  • History of bone marrow/hematopoietic stem cell or solid organ transplantation.
  • Patients deemed unsuitable for participation by the investigator.

Quoted from ClinicalTrials.gov, NCT07592754, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07592754, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07592754